Cystic Fibrosis Weekly Update

Contents:

European Regulators Take Step Toward Possible Approval of Vertex’s New Combo Therapy for 90% of CF Patients
$15M Donation to Support CF Research Program at University of Queensland

European Regulators Take Step Toward Possible Approval of Vertex’s New Combo Therapy for 90% of CF Patients

Nov 01, 2019 07:00 am | Patricia Inacio, PhD

The European Medicines Agency (EMA) has validated Vertex Pharmaceuticals’ application seeking approval for its triple combination — elexacaftor (VX-445), plus tezacaftor, and ivacaftor (Kalydeco) — for cystic fibrosis (CF) patients who cannot use other approved CF disease-modifying treatments or don’t benefit from them as intended. This decision comes days after the U.S. Food and Drug Administration […]
The post European Regulators Take Step Toward Possible Approval of Vertex’s New Combo Therapy for 90% of CF Patients appeared first on Cystic Fibrosis News Today.

$15M Donation to Support CF Research Program at University of Queensland

Oct 31, 2019 07:00 am | Mary Chapman

The University of Queensland (UQ), in Australia, has launched its Queensland Cystic Fibrosis Research Program with a goal of improving the life of people with this disease. This research program is supported by $15 million donation put together by several sources: the Cystic Fibrosis Foundation in the U.S., and in Australia, UQ together with the Children’s Hospital Foundation, the department […]
The post $15M Donation to Support CF Research Program at University of Queensland appeared first on Cystic Fibrosis News Today.